Closure rates and patterns after light silicone oil tamponade for persistent full-thickness macular holes.
Pars plana vitrectomy
Persistent macular hole
Refractory macular hole
Silicone oil
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
13
06
2023
accepted:
16
08
2023
revised:
05
08
2023
medline:
27
11
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
ppublish
Résumé
To report outcomes of re-vitrectomy using light silicone oil (SO) tamponade for persistent macular holes (MHs). We reviewed cases of patients with full-thickness MHs that underwent pars plana vitrectomy (PPV) with air/gas and were re-vitrectomized using light SO tamponade after primary non-closure (persistent MHs). Outcome measures included anatomic closure rates and patterns confirmed by optical coherence tomography (OCT) and changes in best-corrected visual acuity (BCVA). A total of 42 eyes of 41 patients with unsuccessful primary PPV with air/gas were included. After re-vitrectomy with light SO (1000-centistoke), 29 (69%) eyes demonstrated type 1 closure without neurosensory defects in OCT scans, whereas 9 eyes (21%) showed type 2 closure with persisting neurosensory defects. Available data (n = 21) showed a significant mean improvement of BCVA from 0.99 logMAR (SD 0.25, range 0.7-1.3) preoperatively to 0.74 logMAR (SD 0.42, range 0.2-1.5) postoperatively (p = 0.035). The treatment of persistent MHs with PPV and light SO tamponade resulted in high closure rates.
Identifiants
pubmed: 37642749
doi: 10.1007/s00417-023-06215-w
pii: 10.1007/s00417-023-06215-w
pmc: PMC10667392
doi:
Substances chimiques
Silicone Oils
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3481-3488Informations de copyright
© 2023. The Author(s).
Références
Int Ophthalmol. 2020 Sep;40(9):2413-2422
pubmed: 32405956
Graefes Arch Clin Exp Ophthalmol. 2009 Nov;247(11):1471-6
pubmed: 19649646
Eye (Lond). 2021 Aug;35(8):2206-2212
pubmed: 33087884
Retina. 2022 Dec 1;42(12):2258-2266
pubmed: 36053928
J Ophthalmol. 2011;2011:928205
pubmed: 21811669
Am J Ophthalmol. 1982 Oct;94(4):468-72
pubmed: 7137271
Clin Ophthalmol. 2020 Jul 30;14:2171-2183
pubmed: 32801628
Retina. 1998;18(3):286-7
pubmed: 9654428
Br J Ophthalmol. 2003 Aug;87(8):1015-9
pubmed: 12881347
Am J Ophthalmol. 2013 Aug;156(2):326-333.e1
pubmed: 23688710
Ophthalmology. 2021 May;128(5):672-685
pubmed: 33045315
Retina. 2016 Apr;36(4):688-94
pubmed: 26418444
Retina. 2019 Apr;39(4):743-752
pubmed: 29303907
Graefes Arch Clin Exp Ophthalmol. 2016 Nov;254(11):2095-2099
pubmed: 27520464
Graefes Arch Clin Exp Ophthalmol. 2021 Jul;259(7):1781-1790
pubmed: 34076741
Retina. 2016 Jan;36(1):163-70
pubmed: 26200509
Exp Ther Med. 2014 Mar;7(3):742-746
pubmed: 24520279
Eye (Lond). 2002 Mar;16(2):121-5
pubmed: 11988809
Arch Ophthalmol. 2002 Jan;120(1):29-35
pubmed: 11786054
J Ophthalmic Vis Res. 2018 Apr-Jun;13(2):130-137
pubmed: 29719640
Ophthalmologe. 1997 Aug;94(8):545-51
pubmed: 9376691
Surv Ophthalmol. 2022 Jul-Aug;67(4):908-931
pubmed: 35101550
Ophthalmol Retina. 2018 Aug;2(8):757-764
pubmed: 31047526
Br J Ophthalmol. 2021 Jul;105(7):1002-1010
pubmed: 32737034
Ophthalmology. 2013 Dec;120(12):2611-2619
pubmed: 24053995
Eur J Ophthalmol. 2021 Mar;31(2):664-672
pubmed: 32019342
Am J Ophthalmol. 2018 Nov;195:36-42
pubmed: 30071212
Acta Ophthalmol. 2009 Nov;87(8):866-70
pubmed: 18983619
Ophthalmic Surg Lasers Imaging Retina. 2022 Jan;53(1):52-61
pubmed: 34982003
Br J Ophthalmol. 2011 Nov;95(11):1564-7
pubmed: 21355018
J Fr Ophtalmol. 1980;3(2):115-8
pubmed: 7189765
Retina. 2020 Jan;40(1):1-15
pubmed: 31335482
Retina. 2021 Apr 1;41(4):726-734
pubmed: 32732611